



Immunity and Vaccine Development Efforts against Trypanosomatid Parasites

Guest Editors:

Dr. Julio Alonso-Padilla

Barcelona Institute for Global Health (ISGlobal), 08036 Barcelona, Spain

Dr. Pascal Bigey

Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, UTCBS, F-75006 Paris, France; PSL University, ChimieParisTech, F-75005 Paris, France.

Deadline for manuscript submissions:

closed (22 May 2022)

Message from the Guest Editors

Dear Colleagues,

At present, drug treatment is the only therapeutic intervention for Chagas disease and human leishmaniasis, as well as for human and animal African trypanosomiasis. These diseases are caused by the single-cell protozoan parasites *Trypanosoma cruzi* and *Leishmania spp.*, and by *T. brucei* and a group of trypanosomatids including *T. congolense*, *T. evansi*, and *T. vivax*.

In common with other Neglected Tropical Diseases, antitrypanosomatid chemotherapies either entail long-term regimens of administration and/or have severe toxicity associated, compromising treatment adherence. Additionally, treatment efficacies during the chronic phase can be variable, and the appearance of drug resistances has been documented. Therefore, availability of protective or therapeutic vaccines for them would mean a breakthrough towards controlling their impact, which collectively affects several hundred million people worldwide.

This Special Issue will welcome both original research and review articles.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Moriya Tsuji

School of Engineering Medicine,
Texas A&M University, 2121 West
Holcombe Blvd., Suite 1007,
Houston, TX 77030, USA

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (Microbiology) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)